In 2014

TIEN (Tianjin) Pharmaceutical Co. Ltd. Phase one API project was completed and put into

In 2015

Register DMF  in USA

In 2017

The company passed successfully the FDA on-site audit with " zero " 438 

In 2018

Register API in the European Union

In Jan, 2021

TIEN (Tianjin) Pharmaceutical Co. Ltd. Phase II preparation was finished

In Jul, 2021

"Carboprost TMA" successfully passed CDE on-site evaluation

In Dec, 2021

"Alprostadil " passed successfully CDE declaration with status " A " 

In Feb, 2022

"Carboprost Tromethamine " passed successfully CDE declaration with status " A "